How to Choose a Local Agent for Overseas Registration of Imaging Devices?

Overview

The local agent is the legal point of contact between an overseas manufacturer and the local regulatory authority, responsible for submission of registration applications, localisation of technical documentation, post-market adverse event reporting, change notifications, and certificate renewals. To evaluate whether a local agent is suitable, you should first confirm whether the device is classified as a medical device or a radiation device in the target country, as the risk class determines the registration pathway. Next, assess whether existing NMPA registration certificates, CE technical files, FDA 510(k) submissions, or ISO 13485 certification can be reused, and identify which reports require supplementary testing or re-editing.

Selection steps include requesting commercial qualifications, relevant case studies for imaging devices, regulatory team backgrounds, and records of communication with regulatory authorities. Technical interviews should assess whether the agent's engineers understand the device principles. Common risks include choosing an agent based solely on price, which may lead to subsequent additional fees; agents without a local entity; subcontracting to third parties; unclear division of responsibilities; ambiguous certificate ownership; and unresponsiveness during renewal or change processes. The agreement should specify the agent's service scope, fee structure, certificate control, change procedures, and exit mechanisms, as well as establish a post-market communication process.

For multi-country registrations in GHWP member states, Southeast Asia, or the Middle East, it is recommended that an experienced regulatory consultancy coordinates the various local agents, converting technical files into formats acceptable across multiple countries, thereby reducing duplicate work and the risk of deficiencies.

Applicable Scenarios and Core Issues

Imaging devices, including X-ray machines, CT scanners, MRI systems, ultrasound diagnostic devices, and endoscopes, generally require overseas manufacturers to appoint a locally registered entity as a local agent or authorised representative when entering foreign markets. This agent is responsible not only for submitting the registration application but also for ongoing post-market regulatory communication, adverse event reporting, and product change notifications. Selecting the wrong agent can lead to registration delays or, in severe cases, suspension or revocation of the certificate.

The core issue is not simply finding an agent, but finding one that can manage the registration project, understand imaging device technology, and fulfil regulatory obligations throughout the product lifecycle. Imaging devices involve electrical safety, electromagnetic compatibility, radiation safety, image quality, and software validation. An agent with only clerical experience will struggle to respond effectively to requests for additional information or deficiencies.

Companies should establish a selection standard that considers the target country, product classification, registration pathway, and internal resources. Understanding the agent's legal duties first, then assessing professional competence, service scope, and renewal capability, is essential to avoid losing control later.

Registration Judgement Logic

Step 1: Determine Regulatory Scope

Different countries have different definitions of medical devices and exclusions. For example, in some countries, diagnostic X-ray equipment is regulated separately as radiation equipment, while ultrasound diagnostic devices may be managed as medical devices. You should confirm whether the device falls under the jurisdiction of the drug/medical device regulatory authority or the nuclear/radiation regulatory authority before beginning agent screening.

Step 2: Confirm Risk Class and Registration Pathway

GHWP member states generally adopt risk-based classification systems. Imaging devices are typically Class II or Class III, requiring submission of technical documents, quality management system certificates, performance verification, and clinical evidence. Registration pathways vary significantly, with some countries requiring local testing, others accepting overseas reports, and some demanding local clinical data.

Step 3: Inventory Existing Documentation

If you already hold an NMPA registration certificate, CE marking, FDA 510(k) or PMA, ISO 13485 or MDSAP certification, these materials can serve as a foundation. However, each country has its own technical documentation format and language requirements, so localisation is mandatory. The agent should be able to assess which reports can be accepted directly and which need additional testing or re-editing.

Step 4: Define Roles and Responsibilities

In regions such as the EU, ASEAN, and the Middle East, the agent is required to handle regulatory communication, adverse event reporting, and recalls. Confirm that the agent has the necessary regulatory liaison capability, local language skills, and is willing to sign documents assuming responsibility.

Documentation and Evidence

When selecting a local agent, request copies of its business licence or commercial registration, medical device operation permit (if applicable), certificates or authorisation letters from products it has previously represented, and the credentials of regulatory personnel on its service team.

You should also prepare a list of your own technical documentation so that the agent can accurately estimate workload and timelines. For imaging devices, the typical documentation includes:

• Product technical requirements or performance specifications
• Risk management report (ISO 14971)
• Electrical safety and electromagnetic compatibility test reports
• Software lifecycle documentation (if applicable)
• Clinical evaluation report or clinical literature data
• Labels and instructions for use samples

These documents do not need to be submitted in full at the initial stage, but you should build a multi-country registration data package that allows the agent to quickly identify gaps. The agent must also know which documents require notarisation, translation, notarised translation, or Hague apostille.

Ask the agent to provide samples of its communications with regulatory authorities or timelines of registration projects it has handled. This is more reliable than verbal assurances.

Common Mistakes

The most frequent problem is treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local liability relationships.

• Directly translating NMPA files without reorganising evidence according to the target market's registration pathway.
• Submitting too many model variants while test reports, clinical evidence, or label coverage are insufficient.
• Selecting a local agent based only on sales partnership without defining regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistencies among labels, instructions for use, promotional materials, and registration documents, leading to deficiencies or post-market compliance risks.
• Failing to plan for reuse of documentation across multiple countries, resulting in repetitive work and increased cost and cycle times.

Company Preparation Checklist

• Identify target countries and regulatory pathways, and list the steps where an agent's involvement is required.
• Organise product technical files, test reports, and quality management system certificates into a base data package.
• Create a shortlist of candidate agents and request their qualifications, experience, case studies, and team details.
• Conduct technical interviews to confirm that the agent's engineers understand imaging device principles.
• Sign a written agreement specifying the scope of authorisation, term, fees, responsibilities, certificate ownership, and exit mechanisms.
• Establish a registration timeline with milestones and agreed deadlines for responding to deficiencies.
• Set up a post-market communication mechanism, including processes for adverse event reporting and change notifications.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgement is thinking that the local agent is just a filing window. In reality, the agent acts as a legal point of contact between the registration applicant and the certificate holder. Imaging devices are technologically complex, and deficiencies often focus on radiation safety, image quality, and software validation. An agent without relevant project experience cannot effectively address these issues.

Conduct a gap analysis early in the project, comparing the target country's requirements with your existing documentation line by line. Do not rush into signing an agreement. Ask the agent to perform a trial gap assessment and evaluate the quality of the questions it raises.

Most technical documents can be reused, such as ISO 14971 risk management files, IEC 60601 test reports, and software documentation. However, labels and instructions for use must be localised, and clinical data may need to be re-evaluated according to the country's requirements. The agent's most important task is converting these documents into a locally acceptable format.

Certificate control is critical. Ensure that the manufacturer's name appears on the certificate, and that the agent is listed only as an agent, not as the owner or holder of the certificate. Change and renewal procedures must also be clearly defined to prevent certificate invalidity if the agent changes or goes out of business. For multi-country registrations, a coordinated approach with an experienced regulatory agent is recommended to reduce duplicated efforts and the risk of deficiencies.

Business Impact

Effective agent selection and management directly affect registration timelines, total cost, and the ability to maintain market access. Poorly chosen agents can lead to costly rework, delayed market entry, and potential disruption of existing distributions. By building a robust selection framework and contractual safeguards, companies can ensure smoother registrations across multiple jurisdictions and create a scalable compliance model for future market expansions.

FAQ: Common Follow-up Questions

Should I Prioritise Qualifications or Registration Experience?

Both are important, but registration experience is more critical. Qualifications confirm that the agent is legally established, while experience determines whether it can handle the complex issues of imaging devices. Prioritise agents with successful cases in the same product category.

Can the Local Agent Submit Technical Files on Behalf of the Manufacturer?

The agent can serve as a submission channel, but the manufacturer remains responsible for the content and compilation of technical files. Agents typically help with formatting, translation, submission, and follow-up. If an agent claims to fully prepare technical files on its own, you should be wary of compliance risks.

Can One Agent Cover Multiple Countries?

Some regional agents can cover multiple countries, but many jurisdictions require a locally registered entity as the agent. It is important to distinguish between a regional representative and a national agent. A regional coordinator can manage overall strategy, while each country should appoint its own local agent to fulfil legal duties.

Consistency Between Quality System and Evidence

From a regulatory review perspective, quality system documentation is not a standalone certificate. Regulators commonly check that the manufacturer name, production address, product scope, certificate validity, applicable standards, and technical documents are consistent with each other. If the ISO 13485 certificate scope does not cover the product being registered, or if the production address, model numbers, or IFU versions differ from the test reports, you may receive requests for additional information even if you have prepared extensive files.

Before submission, create an evidence consistency checklist that maps product names, model numbers, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management versions, label and IFU versions, and quality system certificates. This simple step can significantly reduce the probability of deficiencies, especially when filing in multiple GHWP member states or submitting multiple product families simultaneously.

Localisation Conversion and Agent Responsibilities

Registration projects in target markets often involve arrangements such as local agents, authorised representatives, importers, or registration holders. You need to confirm whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and long-term market stability.

Labels, instructions for use, and authorisation documents cannot be simply translated. Check local language requirements, product claim boundaries, warning statements, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative details, and after-sales contact information. For companies that already hold CE, FDA, NMPA, or other market authorisations, the focus of localisation is converting reusable evidence into the submission structure accepted by the target country, rather than creating a completely new set of documents.

Post-Market Maintenance and Long-Term Planning

Obtaining registration is not the end of compliance work. You must maintain certificate validity, track changes, manage distributor authorisations, handle complaints, report adverse events, maintain recall procedures, update labels and IFUs, and keep records of regulatory changes. Many companies invest heavily in the registration phase but neglect post-market obligations, which later causes problems such as certificate expiry, gaps in sales, or non-compliance when changes occur.

AIMEILI recommends integrating post-market maintenance into an annual international registration plan. Define target market priorities, build a reusable data package and a list of country-specific gaps, and schedule milestones for submission, deficiency responses, post-market activities, and renewals. This approach not only improves the efficiency of individual country registrations but also builds a replicable compliance capability that reduces the cost of entering new markets from scratch.